Activating Compound | Comment | Organism | Structure |
---|---|---|---|
additional information | ristocetin does not increase granzyme B cleavage in the presence or absence of salt | Homo sapiens |
Application | Comment | Organism |
---|---|---|
medicine | extracellular granzyme B may help control localized coagulation during inflammation | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
S183A | granzyme B active site mutant | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
additional information | back salt progressively inhibits granzyme B-mediated von Willebrand factor cleavage | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
Fibrinogen + H2O | granzyme B is unable to cleave soluble fibrinogen, granzyme B cleaves the matrix form at several sites | Homo sapiens | ? | - |
? | |
additional information | granzyme B has no effect on platelet adhesion and spreading on immobilized collagen. Granzyme B does not cleave glycocalicin (extracellular domain of GPIbalpha) | Homo sapiens | ? | - |
? | |
von Willebrand factor + H2O | granzyme B delays ristocetin-induced platelet aggregation and inhibits platelet adhesion and spreading on immobilized von Willebrand factor under static conditions. In vitro, granzyme B cannot cleave the von Willebrand factor conformer in solution, but cleavage is induced when von Willebrand factor is artificially unfolded or presented as a matrix. Granzyme B cleaves von Willebrand factor with comparable efficiency to proteinase ADAMTS-13 and rapidly processes ultra-large von Willebrand factor multimers released from activated endothelial cells under physiological shear. Granzyme B cleaves the A1 and A3 domains of von Willebrand factor | Homo sapiens | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
GrB | - |
Homo sapiens |